AGEN
Agenus
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
Significant inflow of main funds
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About AGEN
Agenus Inc.
An immuno-oncology company with a broad pipeline targeting cancer and infectious disease
Biological Technology
Invalid Date
02/04/2000
NASDAQ Stock Exchange
316
12-31
Common stock
3 Forbes Road, Lexington, Massachusetts 02421
--
Agenus Inc., founded in 1994, is a Delaware limited liability company. The company is a clinical-stage biotechnology company specializing in the development of therapies that activate the human immune system to fight cancer and infection.
Company Financials
EPS
AGEN has released its 2024 Q4 earnings. EPS was reported at -2.04, versus the expected -2.54, beating expectations. The chart below visualizes how AGEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AGEN has released its 2024 Q4 earnings report, with revenue of 26.84M, reflecting a YoY change of -67.98%, and net profit of -46.81M, showing a YoY change of 3.66%. The Sankey diagram below clearly presents AGEN’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
